The metabolic fate of substrates in humans can be examined by the use of stable isotopes, one of which, [
The past two decades have seen the increased use of stable isotopes to study amino acid metabolism in humans. These isotopic tracer techniques have greatly enhanced our understanding of nutrient daily requirements and metabolism (1) .
For determining the oxidation rates of specifically labeled substrates such as amino acids or glucose, we need to quantify substrate oxidation in each individual by measuring the 13 CO 2 production rate during IV infusion of labeled bicarbonate (2) . The production of 13 CO 2 is made up of total CO 2 production rate and 13 CO 2 enrichment in expired breath. Although total CO 2 production rate is traditionally assessed by indirect calorimetry, 13 CO 2 enrichment is measured by isotopic ratio mass spectrometry. A certain amount of CO 2 , and thus 13 CO 2 as well, is retained in the body. Because this amount is related to caloric intake, a correction factor is necessary to calculate substrate oxidation rates (3) . A method that makes correction factors and indirect calorimetry superfluous is the infusion of NaH 13 CO 3 before the labeled substrate infusion (4). Kien et al. (5) compared IG infusion of [
13 C]bicarbonate with indirect calorimetry by the use of a correction factor. This study showed the validation of the use of dilution stable tracer technique to estimate CO 2 production. However, those authors did not compare the 13 CO 2 enrichment during IV infusion with IG infusion of [
13 C]bicarbonate. The general purpose of this study was to determine whether in preterm infants IG infusion of NaH 13 CO 3 yields the same enrichment as IV infusion at steady state. To this aim, we compared 13 CO 2 enrichment in expired breath during IG and IV infusion of labeled bicarbonate at plateau. In addition, we quantified the minimal tracer infusion time required to establish steady state during IG infusion.
We hypothesized that 13 CO 2 enrichment at steady state would not differ between IG administration and IV administration of [ 13 C]bicarbonate. were clinically stable during the 2-day study. Five of them needed artificial ventilation, and five breathed spontaneously with O 2 supplementation by nasal prong (n ϭ 5). Eight infants tolerated full enteral feeding, and two infants received partial enteral and partial parenteral feeding. For all neonates, the feeding regimen was the same on both study days. All infants were fed through a nasogastric feeding tube because this is a standard procedure in our unit. The study protocol was approved by the Erasmus MC Institutional Review Board, and written and informed consent was obtained from both parents of all neonates.
Tracer protocol. For the purpose of validating this route of labeled sodium bicarbonate the study was designed as a randomized, crossover study. The 10 infants received a primed (10 mol/kg/min) continuous (10 mol/(kg·h) infusion of [ 13 C]bicarbonate (sterile pyrogen free, 99% APE; Cambridge Isotopes, Woburn, MA). The study was set up as a true crossover design: in five infants the IV infusion was started for 6 hours on the first day, followed by the IG infusion on the second day. The other five infants received the IG infusion the first day and the IV infusion the second day. One hour before the start of the study, the usual hourly feeding regimen was changed to continuous drip feeding. Enterally infused tracer was mixed with the milk (either fortified or nonfortified breast milk, or preterm infant formula; Nenatal, Nutricia Nederland B.V., Zoetermeer, The Netherlands) and infused continuously via the nasogastric tube.
Breath samples were obtained by use of the direct sampling method described by van der Schoor et al. (6). Briefly, in mechanically ventilated neonates, a syringe was connected to the ventilator tubing, and breath was taken slowly during expiration with a total volume of 15 mL. When infants were breathing spontaneously, a 6F gastric tube (6 Ch Argyle; Cherwood Medical, Tullamore, Ireland) was placed 1 to 1.5 cm into the nasopharynx, and end-tidal breath was taken slowly with a syringe connected at the end. Collected air was transferred into-10 mL sterile, non-silicon-coated evacuated glass tubes (Van Loenen Instruments, Zaandam, The Netherlands) and stored at room temperature until analysis.
Baseline samples were obtained 15 and 5 min before tracer infusion was started. During the experiment, duplicate 13 C-enriched breath samples were collected every 30 min and every 15 min during the last 45 min of tracer infusion.
Analytic methods. 13 CO 2 isotopic enrichment in expired air was measured by isotope ratio mass spectrometry (ABCA; Europe Scientific, Van Loenen Instruments, Leiden, The Netherlands) and expressed as APE above baseline. The APE was plotted relative to time. Steady state was defined as three or more consecutive points with a slope not different from zero. Estimated body CO 2 production (mmol/kg/h) was calculated for each infant with the following equation (7): Estimated body CO 2 production ϭ IE infusate * tracer infusion rate * 1000 IE breath bicarbonate where IE infusate is the 13 C enrichment of the tracer (APE), IE breath bicarbonate is the 13 C enrichment in the expired air (APE), and tracer infusion rate is the rate of [ 13 C]bicarbonate infusion (mol/kg/h). Statistical analysis. Descriptive data are expressed as mean Ϯ SD. To define the slope of the curve of the two different methods, a repeated measurements linear model was used. Steady state was achieved when the linear factor of the slope was found to be not significantly different from zero (p Ͼ 0.05) (8) . Whole-body CO 2 production and baseline enrichments between the two methods were analyzed by paired t tests. (9) was used to test the null hypothesis if the variance of two-paired measurements (IG and IV infusion) were the same. To detect significant differences between the two-paired measurements, a paired t test could be performed. Pearson's correlation coefficient was performed to show correlation between IG and IV. The analysis of Bland and Altman (10) was performed to show accuracy between the two different infusions. All statistical analyses were performed by the use of SPSS version 11.0 (SPSS, Chicago, IL, USA).
Differences in
steady state between IG and IV administration were also analyzed by paired t tests. Statistical significance was defined as p Ͻ 0.05. Pitman's test
RESULTS
The clinical characteristics of the infants are given in Table  1 . The mean study weight of the infants was 1.18 Ϯ 0.32 kg. The postnatal age at the start of the study was 28 Ϯ 20 d. Their energy intakes did not differ between both study days (p ϭ 0.75). The mean 13 C enrichments, expressed as AP, in breath CO 2 from time point t ϭ 60 to t ϭ 360 min are shown in Fig.  1 . All neonates achieved isotopic steady state in both administration routes. Baseline enrichments did not differ between IG and IV infusion (1.0875 AP Ϯ 0.0022 versus 1.0869 AP Ϯ 0.0338, p ϭ 0.29).
The mean APE at plateau (t 120 -360 ) during IG infusion was 0.0365 Ϯ 0.0055; during IV infusion it was 0.0371 Ϯ 0.0067. IG enrichment was slightly lower, though not significantly, than IV enrichment (p ϭ 0.59).
The Pitman's tests (9) showed no significant difference between variance in IV and IG infusion (p ϭ 0.308), and the Pearson's correlation coefficient was 0.359. Agreement between the two different routes of administration was determined by the analysis of Bland and Altman (10) . Figure 2 shows on the x axis the average of the IV plateau and the IG plateau (n ϭ 10), whereas the y axis shows the difference between the two measurements (n ϭ 10). The mean difference is 0.0006 APE. Note that all measurements lie between the range of the mean difference ϩ2 SD (0.0076 APE) and the mean difference Ϫ2 SD (Ϫ0.0064 APE). The 95% CI of the mean difference is Ϫ0.0019 to 0.0031 APE. Therefore, from 120 min onward, there was no statistically significant difference in CO 2 enrichment in expired air between IV or IG infusion, nor did we find a sequence effect (no significant difference in 13 CO 2 between infants who received NaH 13 CO 3 Key: e ϭ enteral intake; p ϭ parenteral intake; v ϭ ventilation; np ϭ nasal prong.
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IV the first day or those who received NaH 13 CO 3 IG the first day).
The estimated CO 2 production did not differ between the IG (27.68 Ϯ 5.38 mmol/kg/h) and IV (27.67 Ϯ 5.64 mmol/kg/h) infusions (p ϭ 0.99).
Steady state was achieved from 60 min onward when the tracer was infused IV and from 120 min onward when it was infused IG.
DISCUSSION
The main purpose of this study was to validate the use of IG administration of [ 13 C]bicarbonate compared with IV administration for metabolic oxidation studies in preterm infants. Clinical studies in addition to experimental research are of great value in elucidating metabolism and nutrition in preterm infants. Information about amino acid metabolism and protein synthesis and oxidation is needed to provide these infants with optimal nutrition and consequently improved growth and survival.
A principal goal of many tracer kinetic experiments is to determine the oxidation rate of the tracer substance by the appearance in breath of labeled C originating from the tracer (11) . The gold standard for determining whole-body CO 2 production is indirect calorimetry (3) . An alternative method is a primed continuous IV infusion of NaH 13 CO 3 . We found the estimated body CO 2 production (27.67 ϩ 5.64 mmol/kg/h) to be similar to that previously described (0.725 Ϯ 0.021 mol/ kg/day) (12) . Also, others have shown that NaH 13 CO 3 can be adequately used as a method of determining CO 2 production rate (4, 5, 13) . The infusion of labeled bicarbonate before a 13 C-labeled substrate carries the advantage that no correction factor is needed to calculate substrate oxidation. In addition, IG infusion of the tracer reduces the invasiveness of metabolic studies. Finally, in studying the metabolic fate of an enteral substrate, it is preferable to administer the tracer enterally as well.
Hoerr et al. (11) studied in adults the effects of IG and IV infusion of labeled bicarbonate on recovery of 13 C in breath and concluded that administration route did not affect recovery. When it is considered that placing an IV catheter in preterm infants is highly invasive, it is very important to search for methods minimizing discomfort.
To achieve steady state during IG administration, tracer infusion should last at least 120 min. Sample collection is accomplished during steady state. Consequently, breath samples should be obtained from 120 min onward. To prevent intrasubject variation, at least four breath samples should be obtained at 10-min intervals, thus between 120 and 160 min of infusion.
We need to emphasize the small sample size of this study. However, we presented a 95% CI (Ϫ0.0019 to 0.0031 APE) of the mean difference to obtain an impression of a type II error. We considered a difference of Ͻ10% between IG plateau and IV plateau to be acceptable. We calculated the difference of the minimal (Ϫ5%) and maximal (8%) of the 95% CI limit of the average plateau of IG and IV (0.0368 APE). As we assumed, the plateau of IV and IG infusion can vary from Ϫ5% to 8% in the general population.
Additionally, we wish to stress that in metabolic studies in parenterally fed infants, [ 13 C]bicarbonate should preferably be administrated IV.
In conclusion, our findings are consistent with the absence of significant differences in 13 CO 2 enrichment between IG and IV infusion after 120 min of infusion, and therefore it would be valid to infuse [ 13 C]bicarbonate IG for the determination of whole-body CO 2 production rate in preterm infants. 
